Interferon beta-1a biosimilar - CinnaGen

Drug Profile

Interferon beta-1a biosimilar - CinnaGen

Alternative Names: CinnoVex; Rec Hu - IFN beta1a

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator CinnaGen
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Multiple sclerosis

Most Recent Events

  • 25 Jan 2017 CinnaGen plans a phase III trial for Multiple sclerosis in Iran (IM) (IRCT201612306135N8)
  • 22 Jun 2016 No recent reports on development identified - Registered for Multiple sclerosis in Azerbaijan (IM)
  • 31 Dec 2014 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top